new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp

January 2007

You'll hear about a new FDA advisory on the erythropoietin analogues Procrit, Epogen, and Aranesp.

It's based on evidence of an increase in death and cardiovascular events when these drugs are used to boost hemoglobin above 12 g/dL.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote